CHCWM – Cancer & Hematology Centers of West Michigan

BBI-20201001 (Bolt)

BBI-20201001 (Bolt)

Description:   Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors

Mechanism of Action: Immune stimulating antibody drug conjugate – trastuzumab like antibody conjugated to a TLR7/8 payload.  Currently combination with Pembrolizumab.

Target Patient Population: Advanced solid tumor patients with IHC 2+/3+/or Her2 amp on NGS/FISH/CISH. 

Study Design:  Study Drug will be administered IV every 3 weeks